- Home
- CBNA vs NOTV Comparison
CBNA vs NOTV Comparison
Compare CBNA & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- NOTV
- Stock Information
- Founded
- CBNA 2006
- NOTV 1974
- Country
- CBNA United States
- NOTV United States
- Employees
- CBNA N/A
- NOTV N/A
- Industry
- CBNA
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- NOTV Health Care
- Exchange
- CBNA NYSE
- NOTV Nasdaq
- Market Cap
- CBNA 159.8M
- NOTV 137.5M
- IPO Year
- CBNA 2024
- NOTV 1997
- Fundamental
- Price
- CBNA $24.48
- NOTV $1.64
- Analyst Decision
- CBNA Buy
- NOTV Strong Buy
- Analyst Count
- CBNA 3
- NOTV 3
- Target Price
- CBNA $29.67
- NOTV $5.92
- AVG Volume (30 Days)
- CBNA 14.0K
- NOTV 1.2M
- Earning Date
- CBNA 05-15-2025
- NOTV 05-09-2025
- Dividend Yield
- CBNA N/A
- NOTV N/A
- EPS Growth
- CBNA 115.79
- NOTV N/A
- EPS
- CBNA 4.17
- NOTV N/A
- Revenue
- CBNA $53,113,000.00
- NOTV $475,114,000.00
- Revenue This Year
- CBNA N/A
- NOTV $6.07
- Revenue Next Year
- CBNA $22.92
- NOTV $5.74
- P/E Ratio
- CBNA $5.87
- NOTV N/A
- Revenue Growth
- CBNA 74.81
- NOTV N/A
- 52 Week Low
- CBNA $20.01
- NOTV $1.15
- 52 Week High
- CBNA $27.56
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- NOTV 38.13
- Support Level
- CBNA N/A
- NOTV $1.15
- Resistance Level
- CBNA N/A
- NOTV $1.85
- Average True Range (ATR)
- CBNA 0.00
- NOTV 0.44
- MACD
- CBNA 0.00
- NOTV -0.05
- Stochastic Oscillator
- CBNA 0.00
- NOTV 28.16
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.